➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Merck
Harvard Business School
AstraZeneca
McKinsey

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Patent: 10,172,921

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,172,921
Title:Method of treating an inflammatory bowel disease comprising agonists of orexin-1 receptor
Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases. The presents methods relates to a method of treating an inflammatory bowel disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R agonist.
Inventor(s): Couvineau; Alain (Paris, FR), Voisin; Thierry (Paris, FR), Messal; Nassima (Paris, FR), Ogier-Denis; Eric (Paris, FR), Treton; Xavier (Paris, FR)
Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE PARIS DIDEROT--PARIS 7 (Paris, FR) ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR)
Application Number:15/320,827
Patent Claims:see list of patent claims

Details for Patent 10,172,921

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 1998-08-24 ⤷  Free Forever Trial 2034-06-24
Abbvie Inc. HUMIRA adalimumab Injection 125057 2002-12-31 ⤷  Free Forever Trial 2034-06-24
Abbvie Inc. HUMIRA adalimumab Injection 125057 2008-02-21 ⤷  Free Forever Trial 2034-06-24
Abbvie Inc. HUMIRA adalimumab Injection 125057 2013-04-24 ⤷  Free Forever Trial 2034-06-24
Abbvie Inc. HUMIRA adalimumab Injection 125057 2014-09-23 ⤷  Free Forever Trial 2034-06-24
Abbvie Inc. HUMIRA adalimumab Injection 125057 2015-11-23 ⤷  Free Forever Trial 2034-06-24
Abbvie Inc. HUMIRA adalimumab Injection 125057 2016-03-09 ⤷  Free Forever Trial 2034-06-24
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Baxter
AstraZeneca
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.